The American Recovery and Reinvestment Act of 2009 provided $1.1 billion for comparative effectiveness research (CER). The Patient Protection and Affordable Care Act established the Patient-Centered ...

Cancer is extremely political and extremely emotional. That makes a discussion on the economics of cancer treatment tricky. Further, the cost and value of cancer therapies are not discussed properly.

Comparative effectiveness research has been the target of recurrent criticism in some political circles, with opponents claiming it’s the “gateway to rationing” or it encourages “cookbook medicine.” ...

Understanding the clinical nuances of when and to whom services render the greatest benefit requires more research. The type of research that addresses this issue is commonly labeled comparative ...

If there was one place research should be easy to perform, it’s on a disease that’s incredibly common. Further, if there are two generally-accepted strategies to treating symptomatic patients with ...

Five Republican Senators have reintroduced a bill to bar the federal government from undertaking comparative effectiveness research, according to a release by Senator Mike Crapo (R-Idaho). The 2009 ...

The research results must avoid creating unintended access barriers, coverage denials, or arbitrary dollar thresholds that can arise through centralized cost effectiveness determinations. By focusing ...

The goal of comparative effectiveness research is to inform clinical decisions between alternate treatment strategies using data that reflect real patient populations and real-world clinical scenarios ...

Comparative effectiveness research is under attack as a new way to limit access to the best health care. Nothing could be further from the truth—in fact, it’s the exact opposite. Comparative ...

Comparative effectiveness research, a proposed method to cut health care spending, is sharply criticized in a new report identifying numerous negative ramifications of the policy. The report, “Shorter ...

PCORI also is offering up to $200 million through the Phased Large Awards for Comparative Clinical Effectiveness Research (PLACER) PFA, for ambitious, large-scale two-phased trials addressing critical ...

The Patient-Centered Outcomes Research Institute (PCORI) today announced the approval of funding awards totaling more than $165 million for new patient-centered comparative clinical effectiveness ...